Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement

Cristián Juanet, Isabel Hassi, Anila Cara, Cristina García Majado, Jose Arriola-Montenegro, Trisha Laxamana, Gian Marco Berti, Maria J. Vargas-Brochero, Charat Thongprayoon, Jose A. Meade-Aguilar, Samuel D. Falde, Ulrich Specks, Fernando C. Fervenza, Ladan Zand · 2026

Read Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement by Cristián Juanet, Isabel Hassi, Anila Cara, Cristina García Majado, Jose Arriola-Montenegro, Trisha Laxamana, Gian Marco Berti, Maria J. Vargas-Brochero, Charat Thongprayoon, Jose A. Meade-Aguilar, Samuel D. Falde, Ulrich Specks, Fernando C. Fervenza, Ladan Zand (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13586681.txt.

Description

IntroductionAvacopan has shown efficacy as a glucocorticoid-sparing therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but its benefit in patients with severe renal involvement treated with rituximab remains uncertain.MethodsWe conducted a retrospective comparative cohort study at Mayo Clinic including patients with AAV and estimated glomerular filtration rate (eGFR) < 30 ml/min per 1.

Catalog record

CREATORCristián Juanet, Isabel Hassi, Anila Cara, Cristina García Majado, Jose Arriola-Montenegro, Trisha Laxamana, Gian Marco Berti, Maria J. Vargas-Brochero, Charat Thongprayoon, Jose A. Meade-Aguilar, Samuel D. Falde, Ulrich Specks, Fernando C. Fervenza, Ladan Zand
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13586681

Browse the full library · About the Tower of Babel